Skip to main content

Harmony Biosciences Holdings (HRMY) Stock

Harmony Biosciences Holdings Stock Details, Movements and Public Alerts

Stock Details

Harmony Biosciences Holdings (HRMY), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $29.22. Over the past 52 weeks, it has ranged between $25.52 and $40.87. This places the current price at 71.5% of its 52-week high and 14.5% above its 52-week low. Recent trading volume was recorded at 549,793. The 14-day Relative Strength Index (RSI) stands at 31.25, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $36.31 by 19.53%. Similarly, it is below its 200-day moving average of $34.10 by 14.31%. The MACD histogram is -0.91, indicating bearish momentum (MACD Line: -2.20, Signal Line: -1.29).

52-Week Range

$40.87 - $25.52

-28.51% from high · +14.50% from low

Avg Daily Volume

1,246,815

20-day average

100-day avg: 867,721

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

10.66

Below market average

Forward P/E

8.76

Earnings expected to grow

Price to Book

1.92

EV/EBITDA

4.16

EPS (TTM)

$2.71

Price to Sales

1.93

Beta

0.89

Less volatile than market

Q:How is HRMY valued relative to its earnings and growth?
Harmony Biosciences Holdings trades at a P/E ratio of 10.66, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of 8.76 is lower than the current P/E, indicating analysts expect earnings to grow over the next year.
Q:What is HRMY's risk profile compared to the market?
With a beta of 0.89, Harmony Biosciences Holdings is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.92 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

18.30%

Operating Margin

15.80%

EBITDA

$233.80M

Return on Equity

20.70%

Return on Assets

11.50%

Revenue Growth (YoY)

21.10%

Earnings Growth (YoY)

-55.00%

Q:How profitable and efficient is HRMY's business model?
Harmony Biosciences Holdings achieves a profit margin of 18.30%, meaning it retains $18.30 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 15.80% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 20.70% and ROA at 11.50%, the company generates strong returns on invested capital.
Q:What are HRMY's recent growth trends?
Harmony Biosciences Holdings's revenue grew by 21.10% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings decreased by 55.00% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$1.7B

Revenue (TTM)

$868.45M

Revenue/Share (TTM)

$15.11

Shares Outstanding

57.87M

Book Value/Share

$15.07

Asset Type

Common Stock

Q:What is HRMY's market capitalization and position?
Harmony Biosciences Holdings has a market capitalization of $1.7B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 57.87M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does HRMY's price compare to its book value?
Harmony Biosciences Holdings's book value per share is $15.07, while the current stock price is $29.22, resulting in a price-to-book (P/B) ratio of 1.94. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$42.00

43.74% upside potential

Analyst Recommendations

Strong Buy

2

Buy

7

Hold

1

Sell

0

Strong Sell

1

Q:How reliable are analyst predictions for HRMY?
11 analysts cover HRMY with 82% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $42.00 implies 43.7% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on HRMY?
Current analyst recommendations:2 Strong Buy, 7 Buy, 1 Hold, 01 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Apr 12, 2026, 02:47 AM

Technical Indicators

RSI (14-day)

31.25

Neutral

50-Day Moving Average

$36.31

-19.53% below MA-50

200-Day Moving Average

$34.10

-14.31% below MA-200

MACD Line

-2.20

MACD Signal

-1.29

MACD Histogram

-0.91

Bearish

Q:What does HRMY's RSI value tell investors?
The RSI (Relative Strength Index) for HRMY is currently 31.25, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret HRMY's MACD and moving average crossovers?
MACD analysis shows the MACD line at -2.20 below the signal line at -1.29, with histogram at -0.91. This bearish crossover indicates downward pressure. The 50-day MA ($36.31) is above the 200-day MA ($34.10), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently below both MAs, confirming weakness.

Indicators last updated: Feb 27, 2026, 12:37 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for HRMY and get notified when the price changes.

Stay Ahead of the Market with Harmony Biosciences Holdings Alerts

Set up price alerts for Harmony Biosciences Holdings and get notified instantly when the price hits your target. Never miss an important price movement again.